Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 19, 2024BloodOpen Access

Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: DELPHINUS Study

View Full Paper
Ask AI
Bookmark
Share

Authors

TBTeena BhatlaNewark Beth Israel Medical CenterLHLaura HoganStony Brook Children's HospitalDTDavid T. TeacheyChildren's Hospital of Philadelphia

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bhatla et al. (2024) studied this question.

synapsesocial.com/papers/68e5bb23b6db6435875531bchttps://doi.org/10.1182/blood.2024024493
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors2010 · 1,045 citations
  2. 2Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 Protocols2016 · 33 citations
  3. 3Acute Lymphoblastic Leukemia in Children2015 · 2,272 citations
  4. 4Bortezomib reinduction chemotherapy in high‐risk <scp>ALL</scp> in first relapse: a report from the Children's Oncology Group2019 · 102 citations
  5. 5Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab792014 · 226 citations